#1 Clinical Trials Search in Europe

Allergen Extract From Poa Pratensis Pollen, Glutaraldehyde-Modified

This article discusses clinical trials investigating the use of a drug containing allergen extract from Poa Pratensis (Kentucky bluegrass) pollen, modified with glutaraldehyde, for treating allergies. The trials aim to assess the effectiveness and safety of this immunotherapy approach for patients with allergic rhinitis, rhinoconjunctivitis, and mild asthma caused by grass and tree pollen allergies.

Table of Contents

What is Allergen Extract from Poa Pratensis Pollen, Glutaraldehyde-Modified?

Allergen Extract from Poa Pratensis Pollen, Glutaraldehyde-Modified is a specialized medication used in the treatment of grass pollen allergies. It is part of a group of treatments known as allergen extracts.[1] This particular extract is derived from the pollen of Poa pratensis, commonly known as Kentucky bluegrass. The extract is modified using glutaraldehyde, a chemical that alters the structure of the allergens to make them more effective for treatment.

How Does It Work?

This medication works through a process called immunotherapy. By exposing your body to small, controlled amounts of the allergen (in this case, modified grass pollen), your immune system gradually becomes less sensitive to it. Over time, this can reduce your allergic reactions when you’re exposed to grass pollen in your environment.[1]

What Conditions Does It Treat?

Allergen Extract from Poa Pratensis Pollen, Glutaraldehyde-Modified is primarily used to treat:

  • Allergic rhinitis (hay fever) caused by grass pollen
  • Allergic rhinoconjunctivitis (affecting both nose and eyes) due to grass pollen
  • Mild to moderate allergic asthma associated with grass pollen allergy
These conditions can range from intermittent (occurring occasionally) to persistent (ongoing).[1]

How Is It Administered?

This medication is administered as a subcutaneous injection, which means it’s injected just under the skin. The treatment is typically given by a healthcare professional in a clinical setting. The maximum daily dose is 0.5 ml, and the treatment can last up to 12 months.[1]

Current Clinical Trials

As of now, there are ongoing clinical trials to further evaluate the effectiveness and safety of this treatment. These trials are combining the Poa pratensis extract with other grass and tree pollen extracts to create more comprehensive allergy treatments.[1] [2]

Efficacy and Safety

The ongoing clinical trials aim to assess both the efficacy and safety of these allergen extracts. They’re looking at various factors, including:

  • Overall symptom and medication scores during pollen seasons
  • Number of symptom-free and medication-free days
  • Frequency of asthma exacerbations
  • Changes in quality of life
  • Changes in immunological parameters (like specific IgE and IgG4 levels)
These trials are designed to provide comprehensive data on how well the treatment works and its safety profile.[1] [2]

Potential Side Effects

As with any medical treatment, there may be side effects. The clinical trials are closely monitoring for any adverse events, including:

  • Reactions at the injection site
  • Systemic allergic reactions
  • Any other unexpected side effects
It’s important to note that the medication is being tested in a controlled clinical setting to ensure patient safety.[1] [2]

Who Is Eligible for This Treatment?

While the specific criteria may vary, generally, this treatment may be suitable for:

  • Individuals aged 12-65 years
  • Those with confirmed grass pollen allergies
  • Patients with moderate to severe allergic rhinitis or rhinoconjunctivitis
  • Some patients with mild to moderate allergic asthma
However, there are also several conditions that might make someone ineligible for this treatment, such as severe asthma, certain autoimmune diseases, or pregnancy. Always consult with a healthcare professional to determine if this treatment is appropriate for you.[1] [2]

Aspect Details
Study Type Phase III clinical trials
Drug Composition Allergen extracts from grass pollens (including Poa Pratensis) and tree pollens, modified with glutaraldehyde
Administration Method Subcutaneous injection
Target Conditions Moderate to severe allergic rhinitis/rhinoconjunctivitis, with or without mild-moderate controlled asthma
Primary Outcome Overall symptom and medication scores during relevant pollen seasons
Key Secondary Outcomes Symptom-free days, medication-free days, asthma exacerbations, quality of life, immunological parameters
Participant Age Range 12-65 years
Treatment Duration Up to 12 months
Safety Assessments Monitoring of adverse events, including local and systemic reactions

FAQ

  • What is the main purpose of these clinical trials? The main purpose is to evaluate the clinical effectiveness and safety of subcutaneously administered polymerized allergen extracts compared to placebo in patients with allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma.
  • What types of allergies are being targeted in these trials? The trials are targeting allergies to grass pollens (including Poa Pratensis) and tree pollens (such as Juniperus oxycedrus and olive tree).
  • How is the drug administered in these trials? The drug is administered subcutaneously (under the skin) as an injection.
  • What are some of the main outcomes being measured? The main outcomes include overall symptom and medication scores during pollen seasons, symptom-free days, medication-free days, asthma exacerbations, quality of life, and immunological parameters such as IgE and IgG4 levels.
  • Who can participate in these trials? Participants include people aged 12-65 with moderate to severe allergic rhinitis or rhinoconjunctivitis, with or without mild-moderate controlled asthma, who have a confirmed allergy to specific grass and tree pollens.

Ongoing Clinical Trials on Allergen Extract From Poa Pratensis Pollen, Glutaraldehyde-Modified

  • Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Allergen extract: A solution containing proteins from substances that cause allergies, used to diagnose or treat allergic conditions.
  • Glutaraldehyde-modified: A process where the allergen extract is chemically altered using glutaraldehyde to reduce its ability to cause allergic reactions while maintaining its therapeutic effects.
  • Subcutaneous immunotherapy: A treatment for allergies where small amounts of allergens are injected under the skin to help the body build tolerance over time.
  • Rhinitis: Inflammation of the nasal passages, often causing symptoms like runny nose, sneezing, and congestion.
  • Rhinoconjunctivitis: A condition where both the nasal passages and eyes are affected by allergy symptoms.
  • ARIA classification: Allergic Rhinitis and its Impact on Asthma, a system for classifying the severity and duration of allergic rhinitis symptoms.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function used to assess asthma severity.
  • IgE: Immunoglobulin E, an antibody that plays a key role in allergic reactions.
  • IgG4: Immunoglobulin G4, an antibody that may be associated with successful allergen immunotherapy.
  • Visual Analogue Scale (VAS): A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-juniperus-oxycedrus-allergy-vaccine-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis-with-or-without-mild-asthma/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-olive-pollen-allergy-vaccine-for-patients-with-allergic-rhinitis-or-asthma/